115 related articles for article (PubMed ID: 9259397)
1. Loss of heterozygosity at the TP53 gene: independent occurrence from genetic instability events in node-negative breast cancer.
Lizard-Nacol S; Riedinger JM; Lizard G; Glasser AL; Coudray N; Chaplain G; Guerrin J
Int J Cancer; 1997 Aug; 72(4):599-603. PubMed ID: 9259397
[TBL] [Abstract][Full Text] [Related]
2. Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.
Nagai MA; Pacheco MM; Brentani MM; Marques LA; Brentani RR; Ponder BA; Mulligan LM
Br J Cancer; 1994 Apr; 69(4):754-8. PubMed ID: 7908218
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy.
Watatani M; Nagayama K; Imanishi Y; Kurooka K; Wada T; Inui H; Hirai K; Ozaki M; Yasutomi M
Breast Cancer Res Treat; 1993 Dec; 28(3):231-9. PubMed ID: 7912561
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A
Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732
[TBL] [Abstract][Full Text] [Related]
7. High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers.
Contegiacomo A; Pizzi C; De Marchis L; Alimandi M; Delrio P; Di Palma E; Petrella G; Ottini L; French D; Frati L
Int J Cancer; 1995 Mar; 61(1):1-6. PubMed ID: 7705920
[TBL] [Abstract][Full Text] [Related]
8. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
[TBL] [Abstract][Full Text] [Related]
9. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy.
Lizard-Nacol S; Lidereau R; Collin F; Arnal M; Hahnel L; Roignot P; Cuisenier J; Guerrin J
Cancer Res; 1995 Oct; 55(19):4416-9. PubMed ID: 7671254
[TBL] [Abstract][Full Text] [Related]
10. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
11. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
12. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
14. Analysis of genetic alterations related to the development and progression of breast carcinoma.
Nagayama K; Watatani M
Jpn J Cancer Res; 1993 Nov; 84(11):1159-64. PubMed ID: 7903963
[TBL] [Abstract][Full Text] [Related]
15. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
[TBL] [Abstract][Full Text] [Related]
16. Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations.
Denisov EV; Sukhanovskaya TV; Dultseva TS; Malinovskaya EA; Litviakov NV; Slonimskaya EM; Choinzonov EL; Cherdyntseva NV
Genet Test Mol Biomarkers; 2011 Dec; 15(12):901-7. PubMed ID: 21810023
[TBL] [Abstract][Full Text] [Related]
17. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the TP53 gene in human gliomas.
Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
[TBL] [Abstract][Full Text] [Related]
19. Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma.
Gorgoulis VG; Kotsinas A; Zacharatos P; Mariatos G; Liloglou T; Tsoli E; Kokotas S; Fassoulas C; Field JK; Kittas C
Cancer; 2000 Nov; 89(9):1933-45. PubMed ID: 11064350
[TBL] [Abstract][Full Text] [Related]
20. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P; Albonico G; di Iasio MG; Ferretti S; Rinaldi R; Cariello A; Pedriali M; Matteuzzi M; Maestri I; Nenci I
Breast Cancer Res Treat; 2001 Mar; 66(2):135-42. PubMed ID: 11437099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
